M. Niederst

发表

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

B. Bernstein, Y. Drier, L. Sequist, 2017, Clinical Cancer Research.

EMT Twists the Road to PI 3 K

C. Benes, M. Niederst, 2014 .

EMT twists the road to PI3K.

C. Benes, M. Niederst, 2014, Cancer discovery.

IN THE SPOTLIGHT EMT Twists the Road to PI3K

C. Benes, M. Niederst, 2014 .

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

W. Hahn, A. Redig, N. Ilić, 2017, eLife.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

G. Getz, A. Iafrate, L. Sequist, 2016, Nature Medicine.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Sridhar Ramaswamy, Mari Mino-Kenudson, Ryohei Katayama, 2014, Science.

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

M. Mino‐Kenudson, L. Sequist, J. Engelman, 2021, Cancer cell.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

John G Doench, W. Hahn, A. Redig, 2017, eLife.

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

J. Engelman, Jeffrey A Engelman, Matthew J Niederst, 2013, Science Signaling.

Mislocalization of the E3 Ligase, β-Transducin Repeat-containing Protein 1 (β-TrCP1), in Glioblastoma Uncouples Negative Feedback between the Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1) and Akt*

A. Newton, M. Frame, N. Warfel, 2011, The Journal of Biological Chemistry.

Suppression of survival signalling pathways by the phosphatase PHLPP

A. Newton, Audrey K O'Neill, M. Niederst, 2013, The FEBS journal.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

G. Getz, K. Ross, S. Ramaswamy, 2015, Nature Communications.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

L. Sequist, J. Engelman, Jeffrey A Engelman, 2015, The Lancet. Oncology.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

J. Barretina, Jennifer L. Harris, J. Engelman, 2016, Cancer research.

Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output

J. Stender, C. Glass, A. Newton, 2014, Proceedings of the National Academy of Sciences.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Joshua M. Korn, J. Korn, P. Hammerman, 2019, Oncogene.

Disruption of the Interface between the Pleckstrin Homology (PH) and Kinase Domains of Akt Protein Is Sufficient for Hydrophobic Motif Site Phosphorylation in the Absence of mTORC2*

A. Newton, N. Warfel, M. Niederst, 2011, The Journal of Biological Chemistry.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

S. Digumarthy, A. Iafrate, L. Sequist, 2018, JCO precision oncology.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies

Zo, L. Sequist, J. Engelman, 2015 .

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

Distinct evolutionary paths to TKI resistance in NSCLC

J. Engelman, A. Hata, M. Niederst, 2018, Cell cycle.

PHLPP phosphatase regulation of growth factor signaling

M. Niederst, 2011 .

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

L. Sequist, J. Engelman, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C*

A. Newton, J. Brognard, N. Warfel, 2009, Journal of Biological Chemistry.

Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2014 .

Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

L. Sequist, J. Engelman, Matthew G. Oser, 2015, The Lancet. Oncology.

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Frederick J. King, W. Sellers, J. Barretina, 2023, Cell reports.

Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL)

M. O'Hayre, D. Messmer, T. Handel, 2012, Leukemia.

Mechanisms and consequences of the loss of PHLPP 1 phosphatase in chronic lymphocytic leukemia ( CLL )

M. O'Hayre, D. Messmer, T. Handel, 2012 .

Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings

M. Schirle, Philipp Holzer, P. Imbach, 2023, bioRxiv.

Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Jennifer Yang, B. Engels, J. Brogdon, 2021, Blood.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer

John G Doench, C. Vakoc, Xintao Qiu, 2024, bioRxiv.

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.

John G Doench, C. Vakoc, B. Drapkin, 2024, Cancer cell.